# City Therapeutics: Phase 1 study in Stargardt Disease 1, STGD1 (48 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | City Therapeutics |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants |
| NCT ID | NCT07836452 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Stargardt Disease 1; STGD1; Healthy Volunteers |
| Intervention types | drug |
| Target enrollment | 48 |
| Site countries | Australia |
| Posted | 2026-09-23 |
| Planned start | 2026-09 |
| Event | Newly registered study |
| Event date | 2026-09-23 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07836452). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.